PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

FDA 40

FDA Chemotherapy Immunization Hospitals 40

PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

FDA 40

FDA 40

PharmD Live

JANUARY 25, 2022

Diabetes 2, low quality of life, cardiac-related illnesses, osteoarthritis, and more are caused or exacerbated by obesity. During a Routine Flu Shot, a Pharmacist Saves a Patient’s Life Lisa Boylan |Mar-22-18|Categories: Article |Tags: Pharmacy_Value [link]. Improved Diagnostics and Patient Outcomes – [link]. Dean, Troy C.

Adverse Reactions 52

Adverse Reactions Patient Care Communication Hospitals 52

The Checkup by Singlecare

MAY 8, 2023

Belbuca is a good alternative to opioid treatment that needs to be taken around the clock, but it may come with a hefty price tag. mg to 2 mg every 4 hours as needed—adjust according to response IM, SubQ: 0.2 mg to 2 mg every 4 hours as needed—adjust according to response IM, SubQ: 0.2 fibromyalgia ).

Controlled Substances 52

Controlled Substances Dosage Labelling FDA 52